Bristol-Myers Squibb

Senior Director, Process Unit Head Commercial Operations

Boudry, Neuchatel, Switzerland

$200,000 – $300,000Compensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
InternshipJob Type
UnknownVisa
Pharmaceutical Manufacturing, Pharmaceutical OperationsIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant scientific or engineering discipline, along with a minimum of 10 years of experience in pharmaceutical manufacturing, with at least 5 years in a leadership role within commercial operations. Strong leadership and strategic planning skills are essential, as is the ability to manage complex projects and drive continuous improvement. Experience with oral solid dosage manufacturing, including capsules and tableting operations, is required.

Responsibilities

The Senior Director, Process Unit Head Commercial Operations will be responsible for overseeing all drug product manufacturing and packaging activities for the Boudry P1 manufacturing facility, ensuring timely production schedules, maximizing productivity, reducing costs, and increasing efficiencies. They will develop and implement manufacturing strategies, build relationships with internal BMS partners, and drive initiatives to maintain or improve Process Unit performance. This role involves creating and leading a process unit leadership team, partnering with site leadership, and undertaking supportive actions to ensure product delivery. Additionally, the Senior Director will be responsible for conducting short- and long-range talent planning, occasional business-related travel, and acting as a deputy to the General Manager in their absence.

Skills

Oral Solid Dosage Manufacturing
Capsules
Tableting
Manufacturing Strategy
Project Management
Continuous Improvement
Leadership
Strategic Planning
Process Unit Leadership

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI